Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment Options for IDH-Mutant Malignant Gliomas.

Current treatment options in oncology - 1 Dec 2024

Swensen Sasha N, Figuracion Karl Cristie F, Venur Vyshak A, Emerson Samuel, Tseng Yolanda D, Lo Simon S, Ermoian Ralph P, Halasz Lia M

Abstract excerpt

OPINION STATEMENT: As the peak incidence of isocitrate dehydrogenase (IDH)-mutant gliomas is amongst young adults, there is a need to balance tumor control with long term side effects of therapy. Following initial clinical presentation and acquisition of contrasted diagnostic imaging, tissue diagnosis is essential in suspected diffuse glioma. Depending on the location and extent of disease, maximal surgical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Clinical Decision-Making

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Combined Modality Therapy

Share to Disease Management

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Neoplasm Grading

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 39612163
DOI: 10.1007/s11864-024-01280-7
PMCID: PMC13092359

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment Options for IDH-Mutant Malignant Gliomas.PMID 39612163Read ↗

Therapies for IDH-Mutant Gliomas.Semantic proximity Read ↗

Management of Adult Patients With Isocitrate Dehydrogenase-Mutant Gliomas in Australia: An Expert Position Statement From the Cooperative Trials Group for Neuro-Oncology.Semantic proximity Read ↗

Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.Semantic proximity Read ↗

Current Treatment Options for Adult Grade 2 IDH-mutant Diffuse Gliomas in the Vorasidenib Era: Patient Selection, Sequencing, and Practical Management.Semantic proximity Read ↗

Multidisciplinary Management of Isocitrate Dehydrogenase-Mutated Gliomas in a Contemporary Molecularly Defined Era.Semantic proximity Read ↗

Advances in the treatment of IDH-mutant gliomas.Semantic proximity Read ↗

Low-grade IDH -mutant gliomas: from standard post-surgical treatments to novel IDH inhibitorsSemantic proximity Read ↗

The Role of Mutant IDH Inhibitors in the Treatment of Glioma.Semantic proximity Read ↗

Treatment of IDH-mutant glioma in the INDIGO eraSemantic proximity Read ↗

Advances in Treatment of Isocitrate Dehydrogenase (IDH)-Wildtype Glioblastomas.Semantic proximity Read ↗

Management for Different Glioma Subtypes: Are All Low-Grade Gliomas Created Equal?Semantic proximity Read ↗

Targeting IDH-Mutant Glioma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.